Just a moment...Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial - The Lancet thelancet.com Submitted by thelancet4803 on October 21, 2023 at 10:43 PM in business No comments 18